The multi infarct dementia market is expected to experience growth owing to increasing prevalence of brain nerves blockages and strokes. The multi infarct dementia disrupts the flow of the blood in brain and results in a series of slight brain strokes. As stated by National Institute of Health, multi infarct dementia is second largest form of dementia and mostly affects the people above the age of 65. Rapidly increasing geriatric population globally is also a factor driving the multi infract dementia market.
For More Information on “Multi-Infarct Dementia Market Research Reports” visit – http://www.grandviewresearch.com/industry-analysis/multi-infarct-dementia-market
Continuous technological advancements in inhibitors, which are used for the diagnosis of dementia is a prominent factor expected to further propel the multi infarct dementia market over the forecast period. However, absence of brain cell damage treatment procedures along with the major focus on control and prevention of future strokes is anticipated to restrain the intensification of the global multi infarct dementia market over the forecast period.
The pharmacological treatment for multi infarct dementia comprises of cholinesterase inhibitors. Revastigmine is one of the most powerful inhibitors capable to inhibit both acetylcholinesterase and butyrylcholinesterase. Since the low folic acid is a risk factor for dementia, the folic acid supplementation is also an effective inhibitor for the prevention of multi infarct dementia. Other inhibitors for dementia include hydergine, memantine, nimodipine and cytidine 5’- diphoshocholine.
Request TOC of “Multi-Infarct Dementia Market Research Reports” visit – http://www.grandviewresearch.com/industry-analysis/multi-infarct-dementia-market/request-toc
On the basis of drugs used for the prevention of multi infarct dementia, selective serotonin reputak is the most prevailing drug worldwide. Other drugs used for multi infarct dementia are calcium channel blockers (CCBs) and angiotensin converting enzyme inhibitors (ACE inhibitors). Geographically, North America attributed for the largest market share as of 2014 owing to the rising geriatric population base, advanced healthcare infrastructure coupled with increasing incidence rate of dementia in this region. European market is expected to grow owing to similar market traits as that of North America .
Asia Pacific is anticipated to witness lucrative growth owing to the increasing awareness regarding prevention of nerve blockages in this region. Some key players in the global multi infarct dementia market include Novartis Pharmaceuticals, Inc., Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Eisai, Inc and Pfizer, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
Toll Free: 1-888-202-9519
Website: Grand View Research
Blog Site: http://marketshare.blog.com/